In weeks 1 to 12 , the incidence of all adverse events was comparable across arms ( A , 43 % ; B , 38 % ; placebo , 47 % ) and the incidence of infections was not greater than placebo ( 11.1 % , 8.9 % , and 18.6 % for A , B , and placebo ) .